Pompe Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Pompe Disease stocks.

Pompe Disease Stocks Recent News

Date Stock Title
May 16 SNY Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
May 16 SNY Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
May 16 SNY If You'd Invested $10,000 in Novavax a Year Ago, This Is How Much You'd Have Now
May 16 BMRN Third Point top buy and sells in Q1
May 15 BMRN BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain
May 15 BMRN Novo Holdings buys stake in life sciences tools company; BioMarin lays off 170
May 15 SNY Novavax Soars on Sanofi Deal: A Smart Buy or Post-Hype Correction?
May 15 SNY Novavax Stock Just Tripled. Is It Too Late to Buy?
May 14 BMRN BioMarin Pharmaceutical to lay off 170 employees
May 14 BMRN Evercore says biotech ‘winter is finally thawing’
May 14 SNY Sanofi to make €1bn biomanufacturing investment in France
May 14 SNY Does Soaring Novavax Stock Have Enough Fuel to Climb Higher?
May 14 SNY Trending tickers: Anglo American, GameStop, Vodafone, Greggs and Novavax
May 14 SNY Fulcrum Therapeutics Inc (FULC) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
May 14 SNY Exploring Three Dividend Stocks On Euronext Paris
May 13 SNY Barrow, Hanley, Mewhinney & Strauss Bolsters Portfolio with Strategic Additions in Q1 2024
May 13 SNY Novavax (NVAX) Q1 Earnings Miss, Stock Soars on Sanofi Deal
May 13 SNY Meme Mania is Back: Buy these 3 Stocks
May 13 SNY Healthcare Giants Pfizer, AstraZeneca, Sanofi Inject Over $2B To Boost France's Healthcare Sector
May 13 SNY Sanofi strikes $1bn deal with Fulcrum for muscular dystrophy drug
Pompe Disease

Glycogen storage disease type II, also called Pompe disease, is an autosomal recessive metabolic disorder which damages muscle and nerve cells throughout the body. It is caused by an accumulation of glycogen in the lysosome due to deficiency of the lysosomal acid alpha-glucosidase enzyme. It is the only glycogen storage disease with a defect in lysosomal metabolism, and the first glycogen storage disease to be identified, in 1932 by the Dutch pathologist J. C. Pompe.
The build-up of glycogen causes progressive muscle weakness (myopathy) throughout the body and affects various body tissues, particularly in the heart, skeletal muscles, liver and the nervous system.

Browse All Tags